Related Experiment Video
Updated: May 4, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Cimetidine-resistant gastric acid secretion in humans
Abstract:
A 63-year-old white man presented with highly aggressive peptic ulcer disease that was nongastrinoma in cause. Intensive medical therapy, which included intravenous cimetidine, failed to ameliorate the course of the disease. The patient's gastric acid output was entirely uninfluenced by cimetidine administration with demonstrably adequate blood levels of the drug. This is the first reported case of gastric acid secretion resistant to an H-2 receptor antagonist in a clinical, rather than experimental, setting. Other instances of resistance to the acid-reducing properties of this class of drugs may account for some of the treatment failures encountered in clinical trials.
Related Concept Videos
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Mucosal Barrier of the Stomach
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...

